News - MedTech

Details of AMLo Biosciences collapse revealed

The details of the collapse of AMLo Biosciences into administration last month have been revealed. ...

MedTech OrganOx sold in £1.1bn deal

Oxford-based OrganOx has been sold in a mammoth £1.1bn deal. The company’s pioneering liver pe...

Inspiration share price flies as turnaround continues

The impressive turnaround at Inspiration Healthcare Group plc is continuing following major changes ...

Oxford Nanopore founder & CEO to leave after two decades in role

The founder and CEO of FTSE 250 constituent Oxford Nanopore Technologies has revealed that he will s...

Medical tourism meets HealthTech: How Istanbul became a global hub

In a post-pandemic world, international healthcare has entered a new era. Medical tourism is no long...

Sava Technologies raises £14m to commercialise wearable device

London-based startup Sava Technologies has raised £14.2m in Series A funding following promising ea...

CARB-X takes Centauri funding to £9.6m with latest investment

MedTech Centauri Therapeutics has received an extra £3.8m in funding from CARB-X to develop its lea...

Avacta sells Coris for £2.2m in therapeutics shift

Listed MedTech Avacta Therapeutics has sold Coris Bioconcept SRL to 3B BlackBio Dx for an upfront fe...

London MedTech Vicebio to be acquired by Sanofi in £1.2bn deal

A London-based MedTech developing vaccines against life threatening respiratory viral infections has...

FTSE 250 member Oxford Nanopore sees huge share price spike

FTSE 250 constituent Oxford Nanopore Technologies plc has released positive results for the first ha...

Listed MedTech ousts CEO and chair after share price dip

A Surrey-based listed MedTech has undergone a leadership shake up after its CEO and chairman both ag...

Entrepreneur behind £100m exit raises funds for next venture

The entrepreneur behind the £100m exit of OXGENE in 2021 has secured funding for his next venture. ...

Subscribe to our newsletter

    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.